Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Atrial Fibrillation
100%
GARFIELD
100%
Nonischemic Cardiomyopathy
100%
Ischemic Cardiomyopathy
92%
Congestive Heart Failure
28%
All-cause Mortality
21%
Cardiovascular Mortality
21%
Treatment Strategy
14%
Angiotensin-converting Enzyme Inhibitor (ACEi)
14%
Angiotensin Receptor Blockers
14%
Major Bleeding
14%
Systemic Embolism
14%
New-onset Atrial Fibrillation
14%
Oral Anticoagulants
14%
Death Rate
14%
Antiplatelet
14%
Antiplatelet Drugs
14%
Treatment Outcome
7%
Clinical Outcomes
7%
Between-group
7%
Trial Registration
7%
Confidence Interval
7%
Hazard Ratio
7%
Etiology
7%
1-year Follow-up
7%
Non-valvular Atrial Fibrillation
7%
Stroke Risk Factors
7%
Non-interventional
7%
Bleeding Rate
7%
Oral Antiplatelet Agents
7%
Heart Failure Therapy
7%
Poisson Model
7%
Beta-blockers
7%
Event Rate
7%
Oral Anticoagulant Drugs
7%
Medicine and Dentistry
Atrial Fibrillation
100%
Nonischemic Cardiomyopathy
100%
Ischemic Cardiomyopathy
92%
Antithrombotic
35%
Apoplexy
21%
Cardiovascular System
21%
Congestive Heart Failure
21%
Antiplatelet Drug
21%
ACE Inhibitor
14%
Angiotensin Receptor Antagonist
14%
Major Bleeding
14%
Antiplatelet
14%
Mortality Rate
7%
Hazard Ratio
7%
Patient with Congestive Heart Failure
7%
Cause of Death
7%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Nonischemic Cardiomyopathy
100%
Ischemic Cardiomyopathy
92%
Anticoagulant Agent
35%
Congestive Heart Failure
28%
Antithrombocytic Agent
21%
Cerebrovascular Accident
21%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Antiplatelet
14%
Bleeding
14%
Angiotensin Receptor Antagonist
14%
Mortality Rate
7%
Cause of Death
7%